Footnotes

TBT, TM, YG and GGB report no potential conflict of interest. DAL currently receives investigator-initiated research support from Pfizer and recently served as a consultant to Merck in the areas of target identification and validation and new compound development.

This work was supported by National Institutes of Health Grant Nos. MH51234 and P50MH103204.